26 October 2020
Pictured: Med2Mark Clinical Advisor Vinayak Smith, Managing Director Pierre Nathie and Managing Partner David Lester with MTPConnect's Senior Director BMTH Dr Gerard Gibbs and Director BTB Danielle Shand presenting virtually at the Value Add day.
Last week, we hosted a special virtual meeting for our BMTH and BTB funding recipients on what to consider when developing a global MedTech commercialisation strategy.
Experts from Med2Mark, an international consulting practice specialising in the translation of biotech and medtech innovations, shared their stories and top tips.
Managing Director Pierre Nathie, zoomed in from Paris to speak to his experience in health economics assessments, creation of quantification models, and the transfer of value proposition to real-life implementation. Pierre has extensive operational knowledge of healthcare systems in US, Europe and Australia.
Managing Partner David Lester, joined the webinar from Melbourne. David was previously a leader of innovation programs for the Food and Drug Administration (FDA), Pfizer and Pharmacia. David has consulted for multiple government and private organisations in strategic implementation of healthcare technology programs in the US and Australia.
Clinical Advisor Vinayak Smith, a physician, scientist and inventor zoomed in from Melbourne, and shared his career journey that has combined clinical, scientific and commercial expertise.
BMTH Senior Director Dr Gerard Gibbs spoke of the value of these opportunities for the large medtech cohort.
“We now have a large BMTH and BTB cohort with the potential to create new products Australian created innovations to take on international markets,” Dr Gibbs said. “The support from MTPConnect is about adding value and creating opportunities for our innovative funded projects to access advice and guidance from commercialisation. So, we were delighted to have Pierre, David and Vinayak meet with the group to share their experiences.”